thalidomide has been researched along with 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cronstein, B; Mediero, A; Montesinos, MC; Perez-Aso, M; Schafer, PH; Wilder, T | 1 |
1 other study(ies) available for thalidomide and 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine
Article | Year |
---|---|
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.
Topics: Adenosine; Animals; Antirheumatic Agents; Blotting, Western; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cytokines; Gene Expression; Guanine Nucleotide Exchange Factors; Inflammation Mediators; Macrophages; Male; Methotrexate; Mice; Phenethylamines; Phosphodiesterase 4 Inhibitors; Receptor, Adenosine A2A; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thalidomide; Tumor Necrosis Factor-alpha | 2015 |